<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469560</url>
  </required_header>
  <id_info>
    <org_study_id>MDS0306</org_study_id>
    <nct_id>NCT00469560</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Deferasirox in MDS</brief_title>
  <official_title>Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, single arm study on Deferasirox treatment in MDS patients with chronic
      transfusional hemosiderosis.

      Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron
      administered during transfusions and, if needed, to reduce the overload of already present
      iron.

      After an screening phase in which patients are evaluated according to eligibility criteria, a
      one year treatment phase foresees monthly visits to evaluate safety and efficacy signs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been widely shown that an appropriate chelating therapy in chronic anemias transfusion
      dependent can prevent the overstock of iron and can reduce the already existing overstock
      reducing, then, the co-morbidity and improving survival.

      In particular, some authors have shown in MDS affected patients undergoing intensive
      chelating therapy with deferoxamine haematological recovery with a reduction of the need of
      transfusions.

      With the present study, we plan to evaluate the safety and efficacy of a therapy with the new
      oral chelating Deferasirox in MDS patients with transfusional hemosiderosis.

      This is an open label, single arm study on Deferasirox treatment in MDS patients with chronic
      transfusional hemosiderosis.

      Patients will receive daily oral dosis of Deferasirox in order to eliminate the quantity of
      iron administered during transfusions and, if needed, to reduce the overload of already
      present iron.

      After an screening phase in which patients are evaluated according to eligibility criteria, a
      one year treatment phase foresees monthly visits to evaluate safety and efficacy signs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the tolerability and safety profile of Deferasirox in pts with MDS with post-transfusional hemosiderosis</measure>
    <time_frame>On a monthly basis thereafter from baseline assessment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate Deferasirox efficacy as chelation therapy in terms of reduction of serum ferritin levels compared to basal levels</measure>
    <time_frame>At 3, 6, 9, and 12 months from baseline assessment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact Deferasirox iron chelating therapy vs the normal demand of transfusions in a subgroup of pts that will not receive growth factors or chemotherapy according to their basal characteristics.</measure>
    <time_frame>On a monthly basis thereafter from baseline assessment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life evaluation.</measure>
    <time_frame>At 3, 6, 9, and 12 months from baseline assessment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to chelating therapy evaluation.</measure>
    <time_frame>On a monthly basis thereafter from baseline assessment.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Hemosiderosis</condition>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <arm_group_label>Deferasirox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, both males and females, with low and intermediate I risk (IPSS score)
             Myelodysplastic syndrome and transfusion-induced hemosiderosis.

          -  Age &gt;=18 years

          -  Patients who never received chelation therapy or who received a therapy with Desferal
             after a day of wash out

          -  Medical history of at least 20 blood transfusions (equivalent to 100 ml/kg of red
             cells concentrate).

          -  Availability of data concerning blood transfusions during the 12 weeks before
             screening

          -  Serum ferritin &gt;= 1000 µg/L at least twice (at least 2 week interval between the 2
             analysis) during the year before the screening

          -  Life expectancy &gt; 12 months

          -  Availability of at least 3 complete blood counts (before transfusions) during the 12
             weeks before the screening

        Exclusion Criteria:

          -  Diagnosis different from MDS (i.e. myelofibrosis)

          -  Severe renal impairment (creatinine clearance &lt; 60 ml/min)

          -  ALT/AST &gt; 500 U/L

          -  Active B and/or C hepatitis

          -  Patients treated during the past 4 weeks with experimental drugs for MDS (including
             thalidomide, azacitidine, arsenic trioxide). These patients become eligible after a
             &quot;wash out&quot; of at least 4 weeks

          -  Concomitant treatment with another iron-chelating agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele ANGELUCCI, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale &quot;A. Businco&quot;, Cagliari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SOC EMATOLOGIA ASO SS Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist.Ematologia e Oncologia Medica L.e A. Seragnoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTMO-Ematologia Ospedale Binaghi</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;A. Businco&quot;</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia &quot;A.O.R.N. S'Anna e S.Sebastiano&quot;</name>
      <address>
        <city>Caserta</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale Centro per le Malattie del Sangue</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Careggi, Università delgi studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Università degli Studi</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e TMO - Ospedale &quot;A. Cardarelli &quot;- Azienda Ospedaliera di Rilievo Nazionale &quot;A. Cardarelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematol Università di Perugia, Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia- Università degli Studi &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Giovanni e Paolo</name>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, Marchetti M, Morra E, Rebulla P, Visani G, Tura S; Italian Society of Hematology. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002 Dec;87(12):1286-306.</citation>
    <PMID>12495903</PMID>
  </reference>
  <reference>
    <citation>Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001 Dec;22(23):2171-9.</citation>
    <PMID>11913479</PMID>
  </reference>
  <reference>
    <citation>Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica. 1998 Sep;83(9):788-90.</citation>
    <PMID>9825575</PMID>
  </reference>
  <reference>
    <citation>Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, Zurlo A. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003 Sep 15;21(18):3502-11.</citation>
    <PMID>12972527</PMID>
  </reference>
  <reference>
    <citation>Caocci G, Baccoli R, Ledda A, Littera R, La Nasa G. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. Leuk Res. 2007 Feb;31(2):249-52. Epub 2006 Jun 30.</citation>
    <PMID>16814382</PMID>
  </reference>
  <reference>
    <citation>Galanello R. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. Ann N Y Acad Sci. 2005;1054:183-5.</citation>
    <PMID>16339664</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>Chronic transfusional hemosiderosis</keyword>
  <keyword>Deferasirox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hemosiderosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 7, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

